Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05525845
Other study ID # 21-010514
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 8, 2022
Est. completion date August 2025

Study information

Verified date November 2023
Source Mayo Clinic
Contact Megan Schaefer
Phone 507-266-6004
Email RSTINDIVOBESITY@mayo.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate how gut hormones and brain areas respond differently to gastric distention, tasteless calories, or palatable food and how this alters appetite.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date August 2025
Est. primary completion date August 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 50 Years
Eligibility Inclusion Criteria: - BMI 18-25 kg/m^2. - Weight stable for 3 months prior to study entry. - For females: study days will be scheduled during the follicular phase of their menstrual cycle (i.e., the first 13 days (about 2 weeks) of the cycle). - Able to provide written informed consent prior to any study procedures and be willing and able to follow study procedures.. - Ability to perform light to moderate physical activity. Exclusion Criteria: - Any contraindication for MRI scanning. - Any history of childhood (> 95th percentile) or adult obesity (BMI >30 kg/m^2). - Claustrophobia. - High intensity training or physical activity. - Any contraindication for intragastric balloon insertion. - Any allergies to the study meals. - Any history of eating disorder. - Any substance abuse disorder (including alcohol and tobacco). - Any history of psychiatric disorders. - Any cardiovascular, endocrine, pulmonary, neurological, or gastrointestinal comorbidities. - Pregnancy or nursing. - Any history of bariatric surgery or endoscopic bariatric procedure. - Use of any medication or supplement that alters appetite. - Patient has a known history of any condition or factor judged by the investigator to prevent participation in the study or which might hinder study adherence.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Functional Magnetic Resonance Imaging (pCASL-MRI)
MRI's will be performed at multiple points on each visit day.
Intragastric Balloon
Intragastric Balloon will be placed during Visit 2 study day and inflated to maximum tolerated volume. Patient will then be scanned in the MRI.
Elemental Meal
Patient will ingest the tasteless elemental meal until their maximum level of fullness. Once full, the patient will be scanned in the MRI.
Hedonic Meal
Patient will ingest meal of their choice from a local food delivery service and eat until they reach their maximum level of fullness. Once full, the patient will be scanned in the MRI

Locations

Country Name City State
United States Mayo Clinic Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in Cerebral Blood Flow related to hypothalamus The mean difference in cerebral blood flow (CBF) at fullness (satiation) and return to hunger (satiety) to the hypothalamic area. 1 month
Secondary Cerebral Bloodflow related in multiple brain areas The mean difference in cerebral blood flow (CBF) at fullness (satiation) and return to hunger (satiety) to the other brain areas related to food intake regulation. 1 month
Secondary Cerebral Blood Flow between three stimuli The mean difference in cerebral blood flow (CBF) between the 3 different stimuli. 1 month
Secondary Hormone level Differences in hormones levels (ghrelin, GLP-1, CCK, PYY, leptin, insulin, GIP, amylin) at each of the stages (I.e., baseline, fullness, maximal fullness) after the three different stimulations. These hormones will be compared before and after the same stimulation days. The hormone measurements on stimulation days will also be compared to each other. 1 month
Secondary comparison of calories Correlation the caloric consumption to fullness, maximal fullness with degree of cerebral blood flow(CBF) change on PASL MRI. 1 month
Secondary calorie corellation to hormones Correlation the caloric consumption to fullness, maximal fullness with changes in the hormonal levels (ghrelin, GLP-1, CCK, PYY, leptin, insulin, GIP, amylin). 1 month
Secondary hormone level comparison Differences in the hormonal levels (ghrelin, GLP-1, CCK, PYY, leptin, insulin, GIP, amylin) between fullness and hunger after the three different stimulations. These hormones will be compared before and after the same stimulation days. The hormone measurements on stimulation days will also be compared to each other. 1 month
Secondary Time differences in stimuli Differences in time to next meal after maximal fullness after the three different stimulations. 1 month
Secondary Caloric consumption differences in stimuli Differences in the caloric consumption after maximal fullness after the three different stimulations. 1 month
Secondary FitBit measured Physical Activity Measurement of daily physical activity during free-living conditions measured through the use of FitBit tracker over the duration of the study. 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1
Completed NCT04052711 - A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design Phase 1

External Links